Checking fluid buildup in people with chronic heart failure
Tests exams and scans that measure fluid buildup in adults with chronic heart failure.
Plain-language title generated from the registry record
Registry title: Chronic Heart Failure - COngestion eValuation
Key facts
- Where
- Vandœuvre-lès-Nancy, FranceSee the site
Where in France
- CHRU de NancyVandœuvre-lès-Nancy, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pr. Nicolas GIRERD
- Trial code
- NCT05089149
- Record updated
- 5 June 2023
- Original description
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.Read full original descriptionShow less
Évaluation de la Congestion en Ambulatoire Chez Les Patients Atteints d'Insuffisance Cardiaque Chronique. CHF-COV (Chronic Heart Failure - COngestion eValuation)
Heart failure (HF) is a significant cause of death and the leading cause of hospitalization in patients over 65 years of age. Congestion is the main source of symptoms and the leading cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic patients are associated with the risk of developing symptomatic HF. The literature supports a multi-modality / integrative evaluation of congestion, combining clinical examination, laboratory results and ultrasound evaluation.
The main objective of the CHF-COV study is to identify congestion markers (clinical, biological and ultrasound) quantified during a consultation or day hospitalization for the monitoring of chronic HF that are associated with the risk of all-cause death or hospitalization for acute HF within 24 months after day hospitalization.
Inclusion: Patients with chronic acute heart failure admitted in hospital for scheduled day hospitalization or consultation; Age ≥18 years; Patients having received complete information regarding the study design and having signed their informed consent form; Patient affiliated to or beneficiary of a social security scheme.
Exclusion: History of lobectomy or pneumonectomy lung surgery; Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code; Comorbidity for which the life expectancy is ≤ 3 months; Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate <15 ml/min/m2 at inclusion; Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc; Pregnant woman, parturient or nursing mother; Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice); Adult person who is unable to give consent; Person deprived of liberty by a judicial or administrative decision,.